← Back to All US Stocks

DBVTF Stock Analysis - DBV Technologies S.A. AI Rating

DBVTF Nasdaq Biological Products, (No Diagnostic Substances) I0 CIK: 0001613780
Recently Updated • Analysis: Mar 23, 2026 • SEC Data: 2025-09-30
STRONG SELL
95%
Pending
Analysis scheduled

📊 DBVTF Key Takeaways

Revenue: $5.0M
Net Margin: -2,046.0%
Free Cash Flow: $-86.2M
Current Ratio: 1.80x
Debt/Equity: 0.01x
EPS: $-0.82
AI Rating: STRONG SELL with 95% confidence

Investment Thesis

Claude

DBV Technologies is experiencing severe financial distress with collapsing revenue (-73.6% YoY), massive operating losses (-$102M), and negative free cash flow (-$86.2M), indicating the company is burning through its cash reserves at an unsustainable rate. Despite maintaining adequate liquidity currently, the company's fundamental business model is broken with a -2046% net margin, and at current burn rates, cash runway appears critically limited.

DBVTF Strengths

Claude
  • + Strong current liquidity position with $69.8M cash and 1.80x current ratio
  • + Minimal debt burden with only $510K long-term debt and 0.01x debt/equity ratio
  • + Modest insider activity suggests some management engagement despite challenges

DBVTF Risks

Claude
  • ! Revenue collapse of 73.6% YoY indicates failed commercialization or market rejection of core products
  • ! Operating cash burn of $86.2M annually unsustainable given current cash reserves of $69.8M
  • ! Massive operating losses with -2043.8% operating margin suggest fundamental business model failure
  • ! Negative ROE of -193.2% and ROA of -92.4% indicate severe capital inefficiency
  • ! Complete dependence on cash reserves for survival with no path to profitability visible

Key Metrics to Watch

Claude
  • * Quarterly revenue trend - watch for stabilization or further deterioration
  • * Operating cash flow and monthly burn rate - critical for estimating runway
  • * Cash and equivalents balance - monitor depletion timeline
  • * Operating expenses and headcount reduction initiatives - necessary for survival
  • * Product pipeline and regulatory milestone achievements - assess future revenue potential

DBVTF Financial Metrics

Revenue
$5.0M
Net Income
$-102.1M
EPS (Diluted)
$-0.82
Free Cash Flow
$-86.2M
Total Assets
$110.5M
Cash Position
$69.8M

💡 AI Analyst Insight

DBV Technologies S.A. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

DBVTF Profitability Ratios

Gross Margin N/A
Operating Margin -2,043.8%
Net Margin -2,046.0%
ROE -193.2%
ROA -92.4%
FCF Margin -1,726.4%

DBVTF vs Healthcare Sector

How DBV Technologies S.A. compares to Healthcare sector averages

Net Margin
DBVTF -2,046.0%
vs
Sector Avg 12.0%
DBVTF Sector
ROE
DBVTF -193.2%
vs
Sector Avg 15.0%
DBVTF Sector
Current Ratio
DBVTF 1.8x
vs
Sector Avg 2.0x
DBVTF Sector
Debt/Equity
DBVTF 0.0x
vs
Sector Avg 0.6x
DBVTF Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

DBVTF Balance Sheet & Liquidity

Current Ratio
1.80x
Quick Ratio
1.80x
Debt/Equity
0.01x
Debt/Assets
52.2%
Interest Coverage
N/A
Long-term Debt
$510.0K

DBVTF 5-Year Financial Trend

DBVTF 5-year financial data: Year 2020: Revenue $14.7M, Net Income -$172.0M, EPS N/A. Year 2021: Revenue $11.3M, Net Income -$159.6M, EPS N/A. Year 2022: Revenue $5.7M, Net Income -$97.8M, EPS $-1.78. Year 2023: Revenue $15.7M, Net Income -$96.3M, EPS $-1.24. Year 2024: Revenue $15.7M, Net Income -$72.7M, EPS $-0.76.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: DBV Technologies S.A.'s revenue has shown modest growth of 7% over the 5-year period. The most recent EPS of $-0.76 indicates the company is currently unprofitable.

DBVTF Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-1,726.4%
Free cash flow / Revenue

DBVTF Quarterly Performance

Quarterly financial performance data for DBV Technologies S.A. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $1.1M -$27.1M $-0.24
Q2 2025 $1.2M -$27.1M $-0.31
Q1 2025 $753.0K -$27.1M $-0.26
Q3 2024 $1.1M -$16.7M $-0.17
Q2 2024 $1.2M -$20.6M $-0.26
Q1 2024 $1.4M -$20.6M $-0.22
Q3 2023 $2.1M -$16.7M $-0.17
Q2 2023 $1.5M -$16.7M $-0.26

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

DBVTF Capital Allocation

Operating Cash Flow
-$86.0M
Cash generated from operations
Capital Expenditures
$159.0K
Investment in assets
Dividends
None
No dividend program

DBVTF SEC Filings

Access official SEC EDGAR filings for DBV Technologies S.A. (CIK: 0001613780)

📋 Recent SEC Filings

Date Form Document Action
Mar 2, 2026 8-K d110966d8k.htm View →
Feb 2, 2026 4 xslF345X05/form4-02022026_040211.xml View →
Jan 20, 2026 8-K d74681d8k.htm View →
Jan 14, 2026 4 xslF345X05/ownership.xml View →
Dec 19, 2025 4 xslF345X05/tm2533970-1_4seq1.xml View →

Frequently Asked Questions about DBVTF

What is the AI rating for DBVTF?

DBV Technologies S.A. (DBVTF) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are DBVTF's key strengths?

Claude: Strong current liquidity position with $69.8M cash and 1.80x current ratio. Minimal debt burden with only $510K long-term debt and 0.01x debt/equity ratio.

What are the risks of investing in DBVTF?

Claude: Revenue collapse of 73.6% YoY indicates failed commercialization or market rejection of core products. Operating cash burn of $86.2M annually unsustainable given current cash reserves of $69.8M.

What is DBVTF's revenue and growth?

DBV Technologies S.A. reported revenue of $5.0M.

Does DBVTF pay dividends?

DBV Technologies S.A. does not currently pay dividends.

Where can I find DBVTF SEC filings?

Official SEC filings for DBV Technologies S.A. (CIK: 0001613780) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is DBVTF's EPS?

DBV Technologies S.A. has a diluted EPS of $-0.82.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2025-09-30 | Powered by Claude AI